Next Science Ltd
ASX:NXS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.058
0.155
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Next Science Ltd
Revenue
Next Science Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Next Science Ltd
ASX:NXS
|
Revenue
$22.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Revenue
AU$198.6m
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
24%
|
|
|
Polynovo Ltd
ASX:PNV
|
Revenue
AU$127.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
42%
|
CAGR 10-Years
98%
|
|
|
SDI Ltd
ASX:SDI
|
Revenue
AU$110.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Ansell Ltd
ASX:ANN
|
Revenue
$2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Revenue
$12.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
What is Next Science Ltd's Revenue?
Revenue
22.8m
USD
Based on the financial report for Dec 31, 2024, Next Science Ltd's Revenue amounts to 22.8m USD.
What is Next Science Ltd's Revenue growth rate?
Revenue CAGR 5Y
41%
Over the last year, the Revenue growth was 3%. The average annual Revenue growth rates for Next Science Ltd have been 37% over the past three years , 41% over the past five years .